Biophytis S.A. (BPTSY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biophytis S.A. (BPTSY) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 45/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Biophytis S.A. (BPTSY) Resumen de Asistencia Médica y Tuberías
Biophytis S.A. is a clinical-stage biotechnology company developing therapeutics for age-related diseases, including sarcopenia and macular degeneration. Their lead drug candidate, BIO101, addresses neuromuscular diseases and respiratory failure, positioning them in the regenerative medicine market with a focus on resilience pathways.
Tesis de Inversión
Biophytis S.A. presents a high-risk, high-reward investment opportunity in the biotechnology sector. The investment thesis hinges on the successful clinical development and regulatory approval of BIO101 and BIO201. Key value drivers include positive clinical trial results, strategic partnerships, and potential market exclusivity. The company's focus on age-related diseases aligns with growing demographic trends and unmet medical needs. However, the company's negative P/E ratio of -0.07 reflects its current pre-revenue status. Investors should closely monitor clinical trial outcomes and regulatory milestones as key indicators of future success. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may not fully capture the inherent risks of investing in a clinical-stage biotech company.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Biophytis S.A. is a clinical-stage biotechnology company focused on age-related diseases.
- Lead drug candidate BIO101 targets neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD).
- BIO201 is being developed for retinopathies, such as dry age-related macular degeneration and Stargardt disease.
- Collaboration agreement with AFM-Telethon supports the development of BIO101 for DMD.
- The company's P/E ratio is -0.07, reflecting its pre-revenue status.
Competidores y Pares
Fortalezas
- Novel approach targeting resilience pathways.
- Lead drug candidate BIO101 in clinical development.
- Collaboration with AFM-Telethon.
- Experienced management team.
Debilidades
- Clinical-stage company with no current revenue.
- High reliance on successful clinical trial outcomes.
- Limited financial resources.
- OTC market trading with limited liquidity.
Catalizadores
- Upcoming: Clinical trial results for BIO101 in sarcopenia patients.
- Upcoming: Clinical trial results for BIO101 in Duchenne Muscular Dystrophy (DMD) patients.
- Upcoming: Regulatory submissions for BIO101 in various indications.
- Ongoing: Advancement of BIO201 into clinical trials for AMD.
- Ongoing: Potential strategic partnerships and licensing agreements.
Riesgos
- Potential: Clinical trial failures for BIO101 and BIO201.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and need for additional funding.
- Ongoing: OTC market trading with limited liquidity and transparency.
Oportunidades de crecimiento
- BIO101 for Sarcopenia: The global sarcopenia market is projected to reach billions of dollars by 2028, driven by the aging population and increasing awareness of muscle loss. BIO101's potential to improve muscle function and reduce the risk of falls presents a significant growth opportunity. Clinical trials are ongoing, and positive results could lead to regulatory approval and commercialization within the next 3-5 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- BIO101 for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. BIO101's collaboration with AFM-Telethon provides access to expertise and resources for developing a therapy for DMD. The DMD market is expected to grow as new therapies emerge. Regulatory approval could be expedited through orphan drug designation. The timeline for commercialization depends on the success of clinical trials and regulatory review, potentially within 5-7 years.
- BIO101 for COVID-19 Respiratory Failure: The COVID-19 pandemic has highlighted the need for effective treatments for respiratory failure. BIO101's potential to reduce inflammation and improve lung function could address this unmet need. The market size depends on the ongoing prevalence of COVID-19 and the emergence of new variants. Regulatory approval could be accelerated through emergency use authorization. The timeline for commercialization is uncertain but could be within the next 1-3 years.
- BIO201 for Age-Related Macular Degeneration (AMD): AMD is a leading cause of vision loss in older adults. BIO201's potential to slow the progression of dry AMD represents a significant growth opportunity. The AMD market is expected to grow as the population ages. Clinical trials are planned, and positive results could lead to regulatory approval and commercialization within the next 5-7 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- Strategic Partnerships and Licensing Agreements: Biophytis can expand its pipeline and market reach through strategic partnerships and licensing agreements. Collaborating with larger pharmaceutical companies or other biotech firms can provide access to funding, expertise, and distribution networks. Licensing out certain assets can generate revenue and reduce financial risk. The timeline for these opportunities is variable but could occur within the next 1-3 years.
Oportunidades
- Growing market for age-related disease therapies.
- Potential for orphan drug designation for DMD.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Amenazas
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Economic downturn and reduced healthcare spending.
Ventajas competitivas
- Proprietary drug candidates with patent protection.
- Focus on resilience pathways, a novel approach to treating age-related diseases.
- Collaboration with AFM-Telethon for DMD research.
- Expertise in developing orally administered small molecule drugs.
Acerca de BPTSY
Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's core strategy revolves around targeting and activating key biological resilience pathways, which protect against and counteract the effects of various biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that contribute to age-related diseases. Their lead drug candidate, BIO101, is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia, Duchenne muscular dystrophy (DMD), and obesity. BIO101 is also being explored as a treatment for severe respiratory failure in patients suffering from COVID-19. In addition to BIO101, Biophytis is developing BIO201, another orally administered small molecule, aimed at treating retinopathies, including dry age-related macular degeneration and Stargardt disease. Biophytis has a collaboration agreement with AFM-Telethon for the development of BIO101 for DMD, highlighting strategic partnerships to advance their pipeline. The company employs 22 individuals.
Qué hacen
- Develop therapeutics for age-related diseases.
- Target and activate key biological resilience pathways.
- Develop orally administered small molecule drugs.
- Focus on neuromuscular diseases like sarcopenia and DMD.
- Develop treatments for retinopathies like AMD.
- Collaborate with organizations like AFM-Telethon.
Modelo de Negocio
- Develop and commercialize proprietary drug candidates.
- Out-license drug candidates to larger pharmaceutical companies.
- Generate revenue through strategic partnerships and collaborations.
- Secure funding through venture capital and public offerings.
Contexto de la Industria
Biophytis operates within the biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential for successful therapies. The aging global population is driving increased demand for treatments targeting age-related diseases, creating a favorable market environment for companies like Biophytis. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Key trends include personalized medicine, gene therapy, and the use of artificial intelligence in drug discovery. Competitors include BITRF (BioTime Inc), BNGI (Bionomics Ltd), IPIX (Ipix Pharmaceuticals Inc), MCET (MGC Pharmaceuticals Ltd), and PFND (Profound Medical Corp).
Clientes Clave
- Patients suffering from age-related diseases.
- Healthcare providers who prescribe Biophytis's therapies.
- Pharmaceutical companies that may license or acquire Biophytis's drug candidates.
- Research institutions and organizations interested in collaborating with Biophytis.
Finanzas
Gráfico e información
Precio de la acción de Biophytis S.A. (BPTSY): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BPTSY.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BPTSY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BPTSY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BPTSY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Stanislas Veillet
CEO
Stanislas Veillet serves as the CEO of Biophytis S.A., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes roles in venture capital and business development, with a focus on identifying and developing innovative therapies. He has a strong understanding of the regulatory landscape and the challenges of bringing new drugs to market. His leadership is focused on advancing Biophytis's pipeline and securing strategic partnerships.
Historial: Under Stanislas Veillet's leadership, Biophytis has advanced its lead drug candidate, BIO101, into clinical trials for multiple indications, including sarcopenia and DMD. He has also secured a collaboration agreement with AFM-Telethon, a significant milestone for the company. His strategic decisions have focused on targeting unmet medical needs in age-related diseases and building a strong intellectual property portfolio.
Información de ADR de Biophytis S.A. No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BPTSY is a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent reporting requirements than listed companies. It allows US investors to invest in Biophytis S.A. without directly dealing with foreign exchanges.
- Ticker del mercado local: Euronext Growth Paris, France
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: BPTS
Información del mercado OTC de BPTSY
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biophytis S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative and carries higher risks than exchange-listed stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity and trading volume.
- Lack of financial transparency and disclosure.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight.
- Review the company's filings on the OTC Markets website.
- Assess the company's financial health and operational performance.
- Research the management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Consult with a financial advisor.
- Consider the risks associated with investing in OTC stocks.
- Established business operations in France.
- Lead drug candidate in clinical development.
- Collaboration agreement with AFM-Telethon.
- Experienced management team.
- Focus on addressing unmet medical needs.
BPTSY Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BPTSY?
Biophytis S.A. (BPTSY) actualmente tiene una puntuación IA de 45/100, indicando puntuación baja. Fortaleza clave: Novel approach targeting resilience pathways.. Riesgo principal a monitorear: Potential: Clinical trial failures for BIO101 and BIO201.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BPTSY?
BPTSY actualmente puntúa 45/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BPTSY?
Los precios de BPTSY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BPTSY?
La cobertura de analistas para BPTSY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BPTSY?
Las categorías de riesgo para BPTSY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for BIO101 and BIO201.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BPTSY?
La relación P/E para BPTSY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BPTSY sobrevalorada o infravalorada?
Determinar si Biophytis S.A. (BPTSY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BPTSY?
Biophytis S.A. (BPTSY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.